Baxter Hlthcare Patent-Cliff Exposure & CMS Drug Spending Portfolio

Baxter Hlthcare (US): 1 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
California HCAI SB 17 Filings11 WAC filings (max 114.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.